Back to Search
Start Over
Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia
- Source :
- Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p3931-3931, 1p
- Publication Year :
- 2017
-
Abstract
- Molecular monitoring of minimal residual disease (MRD) in Acute Myeloid Leukemia (AML) patients (pts) with mutated NPM1 (NPM1+) is a prognostic tool, not only for predicting disease relapse but also for its potential role to guide pre-emptive therapy in early-stage relapse (Ivey 2016). The utility of MRD detection by multiparameter flow-cytometry (MFC) in the setting of AML pts with a molecular marker is still unclear. We evaluated the prognostic significance of molecular and MFC MRD monitoring on pts outcome and the efficacy of relapse treatment in AML NPM1+ pts at a single Institution.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 130
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56857420
- Full Text :
- https://doi.org/10.1182/blood.V130.Suppl_1.3931.3931